PIK3CA and ovarian carcinoma: A study including 140 patients (breast, cervical, endometrial, and ovarian cancers) from phase I program treated with PI3K/AKT/mTOR inhibitors, measured different potential biomarkers (PIK3CA, KRAS, NRAS, and BRAF) to see if a correlation was possible with the response rate of patients.